Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell Lymphoma

NCT05058755 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

Interventions

DRUG: tislelizumab, azacytidine, lenalidomide
DRUG: tislelizumab, etoposide, pegaspargase

Sponsor

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine